COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY

被引：0
|
作者：
Di Costanzo, A. [1 ]
Uster, A. [2 ]
Vassallo, C. [1 ]
Fiorentino, F. [1 ]
机构：
[1] IQVIA Solut Srl, Milan, Italy
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE117
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE IN FRANCE
    Supiot, R.
    Tardu, J.
    Virely, N.
    Sivignon, M.
    Chollet, J.
    Uster, A.
    Levy, P.
    Massy, Z.
    VALUE IN HEALTH, 2024, 27 (12) : S365 - S365
  • [2] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NETHERLANDS
    Fens, T.
    Weersma, M.
    Postma, M. J.
    Boersma, C.
    de Jong, L.
    VALUE IN HEALTH, 2023, 26 (12) : S132 - S132
  • [3] Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease with or without Albuminuria
    Odawara, Motoki
    Nishi, Hiroshi
    Kodera, Satoshi
    Kondo, Masahide
    Nangaku, Masaomi
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 20 (01): : 50 - 61
  • [4] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE (CKD) MANAGEMENT IN THE UK
    Ramos, M.
    Gerlier, L.
    Uster, A.
    Aguirre, A. R.
    Muttram, L.
    Frankel, A. H.
    Lamotte, M.
    VALUE IN HEALTH, 2023, 26 (12) : S131 - S132
  • [5] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN FOR ADULTS WITH CHRONIC KIDNEY DISEASE (CKD) IN GREECE
    Koulentaki, M.
    Vlahakos, D.
    Tsimihodimos, V
    Smyrnaios, C.
    Delli, E.
    Karpouzos, G.
    Kourlaba, G.
    VALUE IN HEALTH, 2024, 27 (12) : S75 - S75
  • [6] Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial
    Groyer, Harinala
    Supiot, Romain
    Tardu, Jean
    Virely, Nicolas
    Sivignon, Marine
    San, Denis
    Levy, Pierre
    Ustyugova, Anastasia
    Massy, Ziad A.
    CLINICAL DRUG INVESTIGATION, 2024, 44 (11) : 811 - 828
  • [7] Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
    Ramos, Mafalda
    Gerlier, Laetitia
    Uster, Anastasia
    Muttram, Louise
    Frankel, Andrew H.
    Lamotte, Mark
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 777 - 785
  • [8] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
    Mannucci, Edoardo
    Ghetti, Gianni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 85 - 95
  • [9] Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease
    Khine, Annika
    Kwok, Jonas
    Lin, Eugene
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2022, 79 (06) : 780 - 782
  • [10] Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
    Kodera, Satoshi
    Morita, Hiroyuki
    Nishi, Hiroshi
    Takeda, Norifumi
    Ando, Jiro
    Komuro, Issei
    CIRCULATION JOURNAL, 2022, 86 (12) : 2021 - +
12345